Allergy asthma medications cover a broad range of treatments, from everyday inhalers to specialist biologic therapies, and understanding your options is essential for effective management. Allergic asthma is one of the most common forms of asthma in the UK, triggered by allergens such as pollen, house dust mites, and pet dander. Treatment follows a stepwise approach guided by NICE guideline NG80, combining reliever, preventer, and add-on therapies tailored to symptom severity. This article outlines the key medications used in the UK, explains how each works, and clarifies when to seek medical advice — helping patients and carers make informed decisions about their care.

Understanding Allergy-Related Asthma and How It Is Treated

Allergic asthma is triggered by allergens activating IgE-mediated immune responses, causing airway inflammation and narrowing; treatment follows a stepwise approach guided by NICE NG80, combining pharmacological therapy with allergen avoidance.

Allergic asthma is a common form of asthma in the UK, affecting both children and adults. It occurs when exposure to an allergen — such as pollen, house dust mites, pet dander, or mould spores — triggers an immune response that causes inflammation and narrowing of the airways. This leads to the characteristic symptoms of wheezing, breathlessness, chest tightness, and coughing.

The underlying mechanism often involves immunoglobulin E (IgE), an antibody produced by the immune system in response to allergens. When IgE binds to mast cells in the airways, it triggers the release of inflammatory mediators such as histamine and leukotrienes. These substances cause bronchoconstriction, increased mucus production, and airway swelling — all of which contribute to asthma symptoms. It is worth noting that asthma is a heterogeneous condition; not all asthma is IgE-mediated, and some people have overlapping or non-allergic phenotypes.

Treatment for allergic asthma is typically stepwise and aims to achieve two goals: relieving acute symptoms and reducing long-term airway inflammation. Management usually combines pharmacological therapies with allergen avoidance strategies. Understanding which medications are available — and how they work — is essential for patients and carers to manage the condition safely and effectively. In the UK, treatment is guided by NICE guideline NG80 (Asthma: diagnosis, monitoring and chronic asthma management) and NHS recommendations, ensuring that care is evidence-based and proportionate to symptom severity.

Common Medications Used for Allergy Asthma in the UK

UK allergy asthma medications include SABAs, inhaled corticosteroids, ICS/LABA combinations, montelukast, LAMAs, and NICE-approved biologic therapies such as omalizumab and dupilumab, all available on NHS prescription.

There is a range of medications used to manage allergic asthma in the UK, and most are available on NHS prescription. The following are the main categories:

• Short-acting beta-2 agonists (SABAs): e.g., salbutamol (available as Ventolin and other brands) — used as quick-relief inhalers

• Inhaled corticosteroids (ICS): e.g., beclometasone, budesonide, fluticasone — the cornerstone of preventer therapy

• Long-acting beta-2 agonists (LABAs): e.g., salmeterol, formoterol — used only in combination with an ICS; a LABA must never be used alone in asthma

• Leukotriene receptor antagonists (LTRAs): e.g., montelukast — particularly useful in allergic asthma

• Long-acting muscarinic antagonists (LAMAs): e.g., tiotropium — licensed as an add-on therapy in adults with asthma

• Biologic therapies — for severe allergic or eosinophilic asthma (see below)

• Oral corticosteroids: e.g., prednisolone — reserved for acute exacerbations or severe uncontrolled asthma

Montelukast deserves particular mention in the context of allergic asthma, as it blocks leukotriene receptors involved in both the allergic and asthmatic response. It is sometimes prescribed alongside inhaled therapy, especially in patients with co-existing allergic rhinitis. The MHRA has issued a Drug Safety Update noting that montelukast may be associated with neuropsychiatric side effects — including sleep disturbances, mood changes, and behavioural effects — in some patients. Prescribers are advised to discuss these risks before initiating treatment, and patients or carers should report any such changes to their prescriber promptly. Suspected side effects from any medicine can also be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).

Experiencing these side effects? Our pharmacists can help you navigate them →

Biologic therapies are typically reserved for patients with severe, poorly controlled asthma and are initiated by specialist severe asthma services. Several are currently NICE-approved for use in the UK:

• Omalizumab (anti-IgE) — for severe persistent allergic asthma (NICE TA278)

• Mepolizumab (anti–IL-5) — for severe eosinophilic asthma (NICE TA671)

• Reslizumab (anti–IL-5) — for severe eosinophilic asthma (NICE TA479)

• Benralizumab (anti–IL-5 receptor) — for severe eosinophilic asthma (NICE TA565)

• Dupilumab (anti–IL-4/IL-13) — for severe asthma with type 2 inflammation (NICE TA751)

• Tezepelumab (anti-TSLP) — for severe asthma (NICE TA859)

Eligibility for each biologic is defined by specific clinical criteria set out in the relevant NICE technology appraisal. All are administered under specialist supervision.

Reliever, Preventer and Add-On Therapies Explained

Relievers (SABAs) provide rapid symptom relief, preventers (ICS) reduce daily airway inflammation, and add-on therapies — including MART regimens, LAMAs, and triple inhalers — are introduced stepwise when asthma remains uncontrolled.

Understanding the distinction between reliever, preventer, and add-on therapies is fundamental to safe and effective asthma management.

Reliever inhalers typically contain a SABA such as salbutamol. They work by rapidly relaxing the smooth muscle surrounding the airways, providing quick relief from acute symptoms. Reliever inhalers should be used in response to symptoms, not routinely. Frequent use — more than three times a week — may indicate poorly controlled asthma and should prompt a review with a GP or asthma nurse. Note that inhaler colours vary between brands and manufacturers; always check the medicine name on the label rather than relying on colour alone.

Preventer inhalers contain inhaled corticosteroids. These work by reducing airway inflammation over time, thereby decreasing sensitivity to allergens and other triggers. Preventer inhalers must be used every day, even when symptoms are absent, to be effective. Patients using a pressurised metered-dose inhaler (pMDI) are advised to use a spacer device, which improves drug delivery to the lungs and reduces the amount deposited in the mouth and throat. Rinsing the mouth after use further reduces the risk of oral thrush and hoarseness, common local side effects.

Add-on therapies are introduced when asthma remains uncontrolled despite regular use of a preventer inhaler. These include:

• ICS/LABA combination inhalers (e.g., beclometasone/formoterol, fluticasone/salmeterol, budesonide/formoterol) — LABAs must always be prescribed with an ICS in asthma and never used alone

• MART (Maintenance and Reliever Therapy): a regimen using a low-dose ICS–formoterol inhaler for both daily maintenance and as-needed relief. This approach is widely used in UK practice and is outlined in NICE NG80 and BTS/SIGN guidance

• Leukotriene receptor antagonists such as montelukast

• Long-acting muscarinic antagonists (LAMAs) such as tiotropium

• Single-inhaler triple therapy (ICS/LABA/LAMA): e.g., beclometasone/formoterol/glycopyrronium or fluticasone furoate/vilanterol/umeclidinium — an option for selected adults with poorly controlled asthma

• Theophylline — less commonly used due to its narrow therapeutic window and requirement for blood level monitoring

The stepwise approach to adding therapies is outlined in NICE guideline NG80 and ensures that treatment is escalated in a structured, evidence-based manner.

Antihistamines and Other Allergy Treatments Alongside Asthma Care

Antihistamines do not treat asthma directly but managing co-existing allergic rhinitis with antihistamines or intranasal corticosteroids can indirectly improve asthma control, as the nose and lungs share a continuous airway.

Many people with allergic asthma also experience co-existing allergic conditions such as allergic rhinitis (hay fever), eczema, or food allergies. Treating these conditions alongside asthma can significantly improve overall symptom control, as unmanaged upper airway inflammation can worsen lower airway disease.

Antihistamines are commonly used to manage allergic rhinitis and urticaria. They work by blocking H1 histamine receptors, reducing symptoms such as sneezing, itching, and a runny nose. Second-generation antihistamines — including cetirizine, loratadine, and fexofenadine — are preferred due to their non-sedating profile and are widely available over the counter in the UK. It is important to note that antihistamines do not treat asthma directly and must not be used as a substitute for prescribed asthma medications. However, effectively managing allergic rhinitis with antihistamines or other treatments may indirectly improve asthma control, as the nose and lungs share a continuous airway.

Intranasal corticosteroid sprays (e.g., fluticasone nasal spray, mometasone) are recommended by NICE as first-line treatment for moderate-to-severe allergic rhinitis and are considered more effective than antihistamines alone for nasal symptoms. Treating rhinitis effectively is particularly important in allergic asthma.

Allergen immunotherapy (desensitisation) — available as subcutaneous injections or sublingual tablets or drops — is an option for selected patients with confirmed allergen sensitisation. It is always initiated and supervised by a specialist, as there is a risk of allergic reactions including anaphylaxis; patients must be counselled on this before starting. Asthma must be well controlled before commencing immunotherapy. In the UK, sublingual grass pollen immunotherapy (e.g., Grazax) is NICE-approved for severe hay fever in adults (NICE TA201) and may benefit those with co-existing asthma, subject to UK commissioning criteria.

NICE and NHS Guidelines on Managing Allergic Asthma

NICE guideline NG80 sets out a stepwise treatment framework for asthma in the UK, supported by technology appraisals for biologic therapies and NHS requirements for personalised asthma action plans reviewed at least annually.

In the UK, the management of asthma is primarily guided by NICE guideline NG80 (Asthma: diagnosis, monitoring and chronic asthma management). This guideline recommends a stepwise approach to treatment, starting with a SABA reliever and a low-dose ICS preventer, then escalating through add-on therapies — including MART (ICS–formoterol) and combination inhalers — based on symptom control and lung function assessments. The live version of NG80 is available on the NICE website and is subject to ongoing review.

For patients with severe asthma, NICE has issued specific technology appraisals for biologic therapies. These include omalizumab (TA278) for severe persistent allergic asthma, as well as mepolizumab (TA671), reslizumab (TA479), benralizumab (TA565), dupilumab (TA751), and tezepelumab (TA859) for severe eosinophilic or type 2 asthma. All biologic therapies are initiated and monitored by specialist severe asthma services, with eligibility determined by specific clinical and biomarker criteria defined in each appraisal.

The NHS Long Term Plan highlights the importance of personalised asthma action plans, which should be provided to every patient. These written plans outline:

• Daily management: which medications to take and when

• Worsening symptoms: how to adjust treatment if control deteriorates

• Emergency guidance: when to seek urgent medical help

Personalised action plans are also supported by NICE Quality Standard QS25 (Asthma). Regular asthma reviews — at least annually for stable patients — are recommended by the NHS and should include assessment of inhaler technique (including spacer use), adherence, trigger avoidance, and symptom control using validated tools such as the Asthma Control Test (ACT). Pharmacists also play an important role in supporting medication adherence and inhaler technique in community settings.

When to Seek Medical Advice About Your Asthma Medications

Patients should contact their GP or asthma nurse if using a reliever more than three times a week, experiencing side effects, or if symptoms are waking them at night; call 999 immediately during an asthma attack.

Knowing when to contact a healthcare professional is a critical aspect of safe asthma management. Patients should be encouraged to seek advice proactively rather than waiting until symptoms become severe.

Contact your GP or asthma nurse if:

• You are using your reliever inhaler more than three times a week

• Your symptoms are waking you at night

• You have had to take oral steroids (e.g., prednisolone) more than twice in the past year

• You experience side effects from your medications, such as a hoarse voice, oral thrush, or mood changes

• Your inhaler technique feels uncertain or your device has changed

• You are pregnant or planning a pregnancy — most asthma preventers, including inhaled corticosteroids, should be continued during pregnancy as uncontrolled asthma poses greater risks than the medication; always seek a review before making any changes to your treatment

Seek urgent medical attention (call 999 or go to A&E) if you are having an asthma attack. While waiting for help, take one puff of your salbutamol reliever inhaler every 30 to 60 seconds, up to a maximum of 10 puffs, using a spacer if available. Call 999 if your symptoms are not improving, are getting worse, or if you are worried at any point. Do not wait. Signs that require immediate emergency help include:

• Struggling to speak in full sentences due to breathlessness

• Lips or fingernails appearing blue (cyanosis)

• Rapidly worsening symptoms despite using your reliever

It is also important to report any new or unexpected symptoms that may be related to your medications. The MHRA advises patients taking montelukast to report any changes in mood, behaviour, or sleep to their prescriber promptly. Patients on long-term high-dose inhaled corticosteroids should be monitored for systemic effects such as adrenal suppression and reduced bone density; those identified as being at risk of adrenal suppression may be issued a UK Steroid Emergency Card, which provides important safety information in the event of illness or injury.

Reporting side effects: If you think you are experiencing a side effect from any medicine, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Your report helps improve the safety of medicines for everyone.

Regular reviews with your GP, practice nurse, or specialist ensure that your allergy asthma medications list remains appropriate, effective, and as safe as possible for your individual circumstances.

Frequently Asked Questions